Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

NEONEC is a single-phase, phase II study evaluating the efficacy of the 12-month neoadjuvant chemotherapy in patients with locally differentiated digestive NEC. The recommended chemotherapy is based on the current reference combination of platinum (cisplatin or carboplatin) and etoposide (VP16). For anorectal locations, radiochemotherapy is proposed to avoid the morbidity of conventional surgery. The objective of the study is to improve relapse-free survival (RFS) in NEC patients treated with neoadjuvant chemotherapy followed by surgery or chemoradiotherapy. In parallel, we will perform a prospective cohort study with patients whose diagnosis is made during surgery, who have not received neoadjuvant treatment, and who are offered an adjuvant treatment of the same type (combination of platinum and platinum salts and etoposide).

NCT Number	NCT04268121
Lead Sponsor	GERCOR - Multidisciplinary Oncology Cooperative Group Collaborators: Fondation ARCAD
Conditions	Neuroendocrine Carcinoma, Digestive Cancer
Enrollment	78 participants
Start Date	2021-01-05
Primary Completion	2027-01 (estimated)
Study Completion	2031-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-23